Diabetes-induced renal injury in rats is attenuated by suramin

Journal of Pharmacology and Experimental Therapeutics

Volumn 343, Issue 1, 2012, Pages 34-43

  Korrapati, Midhun C ^a   Shaner, Brooke E ^a   Neely, Benjamin A ^b   Alge, Joseph L ^b   Arthur, John M ^c   Schnellmann, Rick G ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CATHEPSIN B; CLUSTERIN; COLLAGEN; COLLAGEN TYPE 1A2; CREATININE; CYSTATIN C; FIBRONECTIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MEMBRANE PROTEIN; PEROXIREDOXIN 1; RETINOL BINDING PROTEIN 4; SMAD3 PROTEIN; SODIUM CHLORIDE; STAT3 PROTEIN; SURAMIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; HYPERGLYCEMIA; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

ANIMALS; BIOLOGICAL MARKERS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY FAILURE, CHRONIC; MALE; NF-KAPPA B; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SURAMIN; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME;

EID: 84866342449     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.196964     Document Type: Article

References (61)

1. Bahmani P, Halabian R, Rouhbakhsh M, Roushandeh AM, Masroori N, Ebrahimi M, Samadikuchaksaraei A, Shokrgozar MA, and Roudkenar MH (2010) Neutrophil gelatinase-associated lipocalin induces the expression of heme oxygenase-1 and superoxide dismutase 1, 2. Cell Stress Chaperones 15:395-403.
2. Balakumar P, Arora MK, Ganti SS, Reddy J, and Singh M (2009) Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions. Pharmacol Res 60:24-32.
3. Barati MT, Merchant ML, Kain AB, Jevans AW, McLeish KR, and Klein JB (2007) Proteomic analysis defines altered cellular redox pathways and advanced glycation end-product metabolism in glomeruli of db/db diabetic mice. Am J Physiol Renal Physiol 293:F1157-F1165. (Pubitemid 47583949)
4. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, Nicocia G, and Buemi M (2009a) Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 4:337-344.
5. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G, and Buemi M (2009b) Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 32:91-98.
6. Catania JM, Chen G, and Parrish AR (2007) Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 292:F905-F911. (Pubitemid 46393417)
7. Collins JM, Klecker RW Jr, Yarchoan R, Lane HC, Fauci AS, Redfield RR, Broder S, and Myers CE (1986) Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol 26:22-26. (Pubitemid 16164515)
8. Covington MD and Schnellmann RG (2012) Chronic high glucose downregulates mitochondrial calpain 10 and contributes to renal cell death and diabetes-induced renal injury. Kidney Int 81:391-400.
9. Fornoni A, Ijaz A, Tejada T, and Lenz O (2008) Role of inflammation in diabetic nephropathy. Curr Diabetes Rev 4:10-17. (Pubitemid 351216880)
10. Goto T, Takeuchi S, Miura K, Ohshima S, Mikami K, Yoneyama K, Sato M, Shibuya T, Watanabe D, Kataoka E, et al. (2006) Suramin prevents fulminant hepatic failure resulting in reduction of lethality through the suppression of NF-κB activity. Cytokine 33:28-35. (Pubitemid 43220349)
11. Hong CY and Chia KS (1998) Markers of diabetic nephropathy. J Diabetes Complications 12:43-60. (Pubitemid 28028762)
12. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
13. Ivashkiv LB and Hu X (2004) Signaling by STATs. Arthritis Res Ther 6:159-168. (Pubitemid 39162378)
14. Jeon YK, Kim MR, Huh JE, Mok JY, Song SH, Kim SS, Kim BH, Lee SH, Kim YK, and Kim IJ (2011) Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci 26:258-263.
15. Kanwar YS, Sun L, Xie P, Liu FY, and Chen S (2011) A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 6:395-423.
16. Keller A, Nesvizhskii AI, Kolker E, and Aebersold R (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 74:5383-5392. (Pubitemid 35215372)
17. Kocic J, Bugarski D, and Santibanez JF (2012) SMAD3 is essential for transforming growth factor-β1-induced urokinase type plasminogen activator expression and migration in transformed keratinocytes. Eur J Cancer 48:1550-1557.
18. Korrapati MC, Shaner BE, and Schnellmann RG (2012) Recovery from glycerol-induced acute kidney injury is accelerated by suramin. J Pharmacol Exp Ther 341:126-136.
19. Kuhad A and Chopra K (2009) Attenuation of diabetic nephropathy by tocotrienol: involvement of NFκB signaling pathway. Life Sci 84:296-301.
20. Lalanne A, Beaudeux JL, and Bernard MA (2011) NGAL: a biomarker of acute and chronic renal dysfunction. Ann Biol Clin 69:629-636.
21. Lin M, Yiu WH, Wu HJ, Chan LY, Leung JC, Au WS, Chan KW, Lai KN, and Tang SC (2012) Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol 23: 86-102.
22. Liu N, He S, Tolbert E, Gong R, Bayliss G, and Zhuang S (2012) Suramin alleviates glomerular injury and inflammation in the remnant kidney. PLoS One 7:e36194.
23. Liu N, Tolbert E, Pang M, Ponnusamy M, Yan H, and Zhuang S (2011a) Suramin inhibits renal fibrosis in chronic kidney disease. J Am Soc Nephrol 22:1064-1075.
24. Liu N, Tolbert E, Ponnusamy M, Yan H, and Zhuang S (2011b) Delayed administration of suramin attenuates the progression of renal fibrosis in obstructive nephropathy. J Pharmacol Exp Ther 338:758-766.
25. Liu N and Zhuang S (2011) Tissue protective and anti-fibrotic actions of suramin: new uses of an old drug. Curr Clin Pharmacol 6:137-142.
26. Ma FY, Liu J, and Nikolic-Paterson DJ (2009) The role of stress-activated protein kinase signaling in renal pathophysiology. Braz J Med Biol Res 42:29-37.
27. Marrero MB, Banes-Berceli AK, Stern DM, and Eaton DC (2006) Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal Physiol 290:F762-F768. (Pubitemid 43724932)
28. Mathew A, Cunard R, and Sharma K (2011) Antifibrotic treatment and other new strategies for improving renal outcomes. Contrib Nephrol 170:217-227.
29. Meinhardt U, Ammann RA, Flück C, Diem P, and Mullis PE (2003) Microalbuminuria in diabetes mellitus: efficacy of a new screening method in comparison with timed overnight urine collection. J Diabetes Complications 17:254-257. (Pubitemid 37040771)
30. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, and Marks JS (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors, JAMA 289:76-79.
31. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, and Steffes MW (2004) Nephropathy in diabetes. Diabetes Care 27 (Suppl 1):S79-S83.
32. Najafian B, Alpers CE, and Fogo AB (2011) Pathology of human diabetic nephropathy. Contrib Nephrol 170:36-47.
33. Nauta FL, Boertien WE, Bakker SJ, van Goor H, van Oeveren W, de Jong PE, Bilo H, and Gansevoort RT (2011) Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 34:975-981.
34. Nayak BK (2005) Changing times, evolving responses. Indian J Ophthalmol 53:1-3.
35. Nesvizhskii AI, Keller A, Kolker E, and Aebersold R (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75:4646-4658. (Pubitemid 37082259)
36. Nicholas SB, Liu J, Kim J, Ren Y, Collins AR, Nguyen L, and Hsueh WA (2010) Critical role for osteopontin in diabetic nephropathy. Kidney Int 77:588-600.
37. Nielsen SE, Hansen HP, Jensen BR, Parving HH, and Rossing P (2011) Urinary neutrophil gelatinase-associated lipocalin and progression of diabetic nephropathy in type 1 diabetic patients in a four-year follow-up study. Nephron Clin Pract 118:c130-135.
38. Ohga S, Shikata K, Yozai K, Okada S, Ogawa D, Usui H, Wada J, Shikata Y, and Makino H (2007) Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation. Am J Physiol Renal Physiol 292:F1141-F1150. (Pubitemid 46578056)
39. Østergaard J, Hansen TK, Thiel S, and Flyvbjerg A (2005) Complement activation and diabetic vascular complications. Clin Chim Acta 361:10-19. (Pubitemid 41382606)
40. Ozer JS (2010) A guidance for renal biomarker lead optimization and use in translational pharmacodynamics. Drug Discov Today 15:142-147.
41. Pang M, Ma L, Gong R, Tolbert E, Mao H, Ponnusamy M, Chin YE, Yan H, Dworkin LD, and Zhuang S (2010) A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int 78:257-268.
42. Rahimi RA and Leof EB (2007) TGF-β signaling: a tale of two responses. J Cell Biochem 102:593-608. (Pubitemid 47557414)
43. Roudkenar MH, Halabian R, Bahmani P, Roushandeh AM, Kuwahara Y, and Fukumoto M (2011) Neutrophil gelatinase-associated lipocalin: a new antioxidant that exerts its cytoprotective effect independent on heme oxygenase-1. Free Radic Res 45:810-819.
44. Roudkenar MH, Halabian R, Ghasemipour Z, Roushandeh AM, Rouhbakhsh M, Nekogoftar M, Kuwahara Y, Fukumoto M, and Shokrgozar MA (2008) Neutrophil gelatinase-associated lipocalin acts as a protective factor against H2O2 toxicity. Arch Med Res 39:560-566. (Pubitemid 352033610)
45. Roudkenar MH, Kuwahara Y, Baba T, Roushandeh AM, Ebishima S, Abe S, Ohkubo Y, and Fukumoto M (2007) Oxidative stress induced lipocalin 2 gene expression: addressing its expression under the harmful conditions. J Radiat Res 48:39-44. (Pubitemid 46219475)
46. Satoskar AA, Shapiro JP, Bott CN, Song H, Nadasdy GM, Brodsky SV, Hebert LA, Birmingham DJ, Nadasdy T, Freitas MA, et al. (2012) Characterization of glomerular diseases using proteomic analysis of laser capture microdissected glomeruli. Mod Pathol 25:709-721.
47. Sharma B, Balomajumder C, and Roy P (2008) Hypoglycemic and hypolipidemic effects of flavonoid rich extract from Eugenia jambolana seeds on streptozotocin induced diabetic rats. Food Chem Toxicol 46:2376-2383.
48. Sharma K, Jin Y, Guo J, and Ziyadeh FN (1996) Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:522-530.
49. Shimizu H, Negishi M, Shimomura Y, and Mori M (1992) Changes in urinary retinol binding protein excretion and other indices of renal tubular damage in patients with non-insulin dependent diabetes. Diabetes Res Clin Pract 18:207-210. (Pubitemid 23032612)
50. Soetikno V, Sari FR, Veeraveedu PT, Thandavarayan RA, Harima M, Sukumaran V, Lakshmanan AP, Suzuki K, Kawachi H, and Watanabe K (2011) Curcumin ameliorates macrophage infiltration by inhibiting NF-κB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr Metab (Lond) 8:35.
51. Soldatos G and Cooper ME (2008) Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res Clin Pract 82 (Suppl 1):S75-S79.
52. Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, and Kim MJ (2006) Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-κ in type 2 diabetic patients with advanced kidney disease. Nephrol Dial Transplant 21:683-689. (Pubitemid 43372915)
53. Suzuki H, Uchida K, Nitta K, and Nihei H (2004) Role of mitogen-activated protein kinase in the regulation of transforming growth factor-κ-induced fibronectin accumulation in cultured renal interstitial fibroblasts. Clin Exp Nephrol 8:188-195. (Pubitemid 39421367)
54. Tada H, Tsukamoto M, Ishii H, and Isogai S (1994) A high concentration of glucose alters the production of tPA, uPA and PAI-1 antigens from human mesangial cells. Diabetes Res Clin Pract 24:33-39. (Pubitemid 24213891)
55. Tan AL, Forbes JM, and Cooper ME (2007) AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 27:130-143. (Pubitemid 46550311)
56. Tang SC, Leung JC, and Lai KN (2011) Diabetic tubulopathy: an emerging entity. Contrib Nephrol 170:124-134.
57. Wang GG, Lu XH, Li W, Zhao X, and Zhang C (2011) Protective effects of luteolin on diabetic nephropathy in STZ-induced diabetic rats. Evid Based Complement Alternat Med 2011:323171.
58. Wu CC, Sytwu HK, Lu KC, and Lin YF (2011) Role of T cells in type 2 diabetic nephropathy. Exp Diabetes Res 2011:514738.
59. Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214:199-210.
60. Zhang PP, Zhan JF, Xie HL, Li LS, and Liu ZH (2010) Evaluation of glomerular filtration rate using cystatin C in diabetic patients analysed by multiple factors including tubular function. J Int Med Res 38:473-483.
61. Zhuang S, Lu B, Daubert RA, Chavin KD, Wang L, and Schnellmann RG (2009) Suramin promotes recovery from renal ischemia/reperfusion injury in mice. Kidney Int 75:304-311.